Cite
HARVARD Citation
Shore, N. et al. (n.d.). 2502 TAK-385, an oral GnRH antagonist: efficacy and safety results from a randomized phase 2 trial in prostate cancer patients (pts). European journal of cancer. pp. S474-. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Shore, N. et al. (n.d.). 2502 TAK-385, an oral GnRH antagonist: efficacy and safety results from a randomized phase 2 trial in prostate cancer patients (pts). European journal of cancer. pp. S474-. [Online].